Adverse Reaction to Omalizumab in Patients with Chronic Urticaria: Flare Up or Ineffectiveness?
,
Abstract
Omalizumab is a recombinant humanized anti-Ig E monoclonal antibody used as the third line treatment of chronic spontaneous urticaria (CSU). We report four patients with severe antihistamine-resistant CSU, who developed angioedema, anaphylaxis and/or flare up of urticaria at different times following omalizumab therapy.
1. Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014; 69(7):868-87.
2. Colgecen E, Ozyurt K, Irfan Gul A, Utas S. Evaluation of etiological factors in patients with chronic urticaria. Acta Dermatovenerol Croat 2015; 23(1):36-42.
3. Maurer M, Weller K, Bindslev-Jensen C, Giménez-Arnau A, Bousquet PJ, Bousquet J, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy 2011; 66(3):317–30.
4. Spector SL, Tan RA. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol 2007; 99(2):190–3.
5. McCormack PL. Omalizumab: a review of its use in patients with chronic spontaneous urticaria. Drugs 2014;74(14):1693-9.
6. Kaplan AP, Joseph K, Maykut RJ, Geba GP, Zeldin RK.Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 2008; 122(3):569–73.
7. McKeage K. Omalizumab: a review of its use in patients with severe persistent allergic asthma. Drugs 2013;73(11):1197–212.
8. Licari A, Marseglia A, Caimmi S, et al. Omalizumab in Children. Paediatric Drugs 2014; 16(6):491-502.
9. Saini SS, Bindslev-Jensen C, Maurer M, Grob JJ, Bülbül Baskan E, Bradley MS, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol 2015; 135(3):925.
10. Maurer M, Rosén K, Hsieh HJ, Saini S, Grattan C, Gimenéz-Arnau A, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria 2013; N Engl J Med 2013; 368(10):924–35.
11. Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali JL, Conner E, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol 2013; 132(1):101–9.
12. Limb SL, Starke PR, Lee CE, Chowdhury BA. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol 2007; 120(6):1378-81.
13. Cox L, Platts-Mills TA, Finegold I, Schwartz LB, Simons FE, Wallace DV; American Academy of Allergy, Asthma & Immunology; American College of Allergy, Asthma and Immunology. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 2007; 120(6):1373-7.
14. Price KS, Hamilton RG. Anaphylactic reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc 2007; 28(3):313-9.
15. Kim HL, Leigh R, Becker A. Omalizumab: Practical considerations regarding the risk of anaphylaxis. Allergy Asthma Clin Immunol 2010; 6(1):32.
16. Barry PJ, O'Mahony A, Finnegan C, O'Connor TM.Delayed allergic reactions to omalizumab: are patients reporting all cases? J Allergy Clin Immunol 2008;121(3):785-6.
| Files | ||
| Issue | Vol 15, No 1 (2016) | |
| Section | Case Report(s) | |
| Keywords | ||
| Chronic urticaria Omalizumab Adverse reaction | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
